Print

The buzz around MonaLisa Touch

https://www.facingourrisk.org/XRAY/monalisa-touch
Full article: http://www.foxnews.com/health/2017/05/22/is-laser-treatment-for-vaginal-atrophy-safe.html

THIS INFORMATION HAS BEEN UPDATED. The FDA issued an alert in July, 2018 noting that laser or radiofrequency devices that have received FDA clearance are ONLY cleared for treating abnormal or pre-cancerous cervical or vaginal tissue and genital warts and have NOT been approved for vaginal rejuvenation. There are currently clinical trials enrolling women to study whether laser and radiofrequency devices can improve vaginal atrophy and other menopausal symptoms. 

For many young breast cancer survivors and high-risk women, the side effects from early menopause after treatment and surgery can negatively impact their personal lives. This XRAYS looks at one of the many recent media articles on a laser procedure called MonaLisa Touch. The article, "Is Laser Treatment for Vaginal Atrophy Safe?"  was published online in 2017 by FOX News and written by Dr. Manny Alvarez. XRAYS will discuss what this laser procedure actually is and how it may impact a young breast cancer patient’s life after treatment. (1/19/18)

Expert Guidelines

The National Comprehensive Cancer Network (NCCN) provides cancer risk management guidelines for people with inherited mutations linked to cancer. In their guidelines on risk management for women at high risk for ovarian cancer, the NCCN panel states: 

The North American Menopause Society is a professional society of experts in the field of menopause.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following research studies related to sexual health are enrolling patients.

Multiple cancers

Breast cancer 

Colorectal cancer

Prostate cancer

The following are studies on menopause and menopause management for survivors and previvors:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.